What time of day should CJC-1295 and ipamorelin be administered?
Most research protocols using CJC-1295 No DAC + ipamorelin administer pre-sleep (within 30 minutes of bedtime) on a fasted-stomach basis to align the induced GH pulse with the natural pituitary GH-secretion peak that occurs early in sleep. Twice-daily protocols often add a morning fasted dose; pre-workout dosing is the third common timing pattern.
What the research literature says
The pre-sleep timing rationale derives from the natural circadian pattern of pituitary GH secretion. Native GH release peaks in the early hours of sleep, with smaller pulses through the day. Pre-sleep administration of a GHRH agonist + GH secretagogue combination produces an induced GH pulse aligned with this natural peak, summing rather than displacing the endogenous rhythm. The natural pulsatility framework is consolidated in the Ionescu work on pulsatile GH secretion during GHRH analogue stimulation (PMID 17018654).
The fasted-stomach requirement reflects the GH-secretion biology — elevated blood glucose, free fatty acids, or insulin can blunt the GH-release response. Most protocols recommend at least 2 hours past the last meal before administration. The Raun characterisation work for ipamorelin established the dose-response framework that supports the typical 100-200 mcg per-dose tier (PMID 9849822).
Twice-daily protocols add a morning fasted dose to produce a second induced GH pulse during the daytime. Pre-workout dosing is the third pattern, used in research contexts studying GH-axis pharmacology in exercise-physiology frameworks. The combined CJC-1295 + Ipamorelin Blend format is administered as a single injection at the chosen time, delivering both compounds simultaneously.
Why this matters in research context
Administration timing is one of the most consequential research-protocol design parameters for GH-axis compounds. The pre-sleep fasted dose maximises alignment with the natural GH-secretion rhythm; deviations from this pattern can reduce the magnitude of the induced GH pulse and complicate downstream IGF-1 axis measurements. Researchers running dose-response or time-course studies should standardise the administration timing across the protocol.
Related compounds
- CJC-1295 No DAC 10mg — GHRH-analogue component
- Ipamorelin 10mg — ghrelin-receptor-agonist component
- CJC-1295 + Ipamorelin Blend — combined-formulation single vial
Related research questions
- Can CJC-1295 be stacked with ipamorelin?
- What is the half-life of CJC-1295 No DAC?
- What is the half-life of ipamorelin?
References
- Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998;139(5):552-561. [PMID 9849822]
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab 2006;91(12):4792-4797. [PMID 17018654]
- Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab 2006;91(3):799-805. [PMID 16352683]
Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. Every compound in the Ronin catalog is sold strictly for laboratory and research use only.